You are here

Share:

A Triple Combination HIV Microbicide

A Triple Combination HIV Microbicide

Summary
Three anti-HIV proteins- the antiviral lectin cyanovirin, the antiviral lectin griffithsin, and the monoclonal antibody 2G12- have been successfully expressed in the same rice seed. The co-expression allows for a low cost, stable production method for a triple anti-HIV microbicide for the prevention of HIV. The National Cancer Institute (NCI) seeks licensees for the invention microbicide and production method.
NIH Reference Number
E-137-2016
Product Type
Keywords
  • Microbicide, HIV, Antibody, Lectin, Antiviral, Sexually Transmitted Diseases, Acquired Immunodeficiency Syndrome, O’Keefe
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

The HIV-positive population continues to rise despite a worldwide decline in the rates of infection caused by human immunodeficiency virus (HIV).  The HIV virus continues to spread due to a lack of effective vaccines and pre-exposure prophylaxis methods, even though the availability and effectiveness of antiretroviral therapy has helped reduce acquired immunodeficiency syndrome (AIDS)-related deaths. 

Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Lleida, developed a triple combination microbicide for the prevention of HIV and other sexually transmitted diseases. The microbicide is comprised of an endosperm, the anti-HIV monoclonal antibody 2G12, and the antiviral lectins griffithsin and cyanovirin. The researchers have generated the microbicide combination in transgenic plants as an efficient and cost-effective production method. 

Potential Commercial Applications
  • Effective anti-HIV microbicide with activity against other viruses as well (HSV, HCV)
Competitive Advantages
  • Low cost, stable production method
  • Stable and long-term storage compatible rice seed
Inventor(s)

Barry OKeefe (NCI), Paul Christou (University of Lleida), Evangelia Vavamka (University of Lleida), Teresa Capell (University of Lleida)

Development Stage
Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number 62/591,569, Filed 28 Nov 2017
Related Technologies
  • E-025-2006
  • E-117-1995
Therapeutic Area
Updated
Tuesday, August 14, 2018